Skip to main content
Edwards Lifesciences Logo

From one heart to over 500,000 lives touched.

Inspiring results hero

Together, we are building a comprehensive body of evidence to drive innovation and advance patient care.

MOMENTIS Study of the MITRIS RESILIA Valve: One of the Largest Core-Lab Adjudicated Surgical Mitral Valve Replacement (MVR) Studies

Results at 1 year

An ongoing prospective, observational, post-market, single-arm, real-world evidence study in 351 North American adults with a dysfunctional native or prosthetic mitral valve who required replacement with a MITRIS RESILIA Mitral Valve.1

100%

Freedom from SVD

99.7%

Freedom from valve-related death

99.7%

Freedom from valve-related reintervention

For more details, download the clinical infographic.

momentis-study
Explore the clinical data

At the 1-year follow-up, the MOMENTIS study demonstrated promising results for real-world mitral valve patients with the MITRIS RESILIA mitral valve.

MOMENTIS study follow-up is ongoing and will continue through 10 years

COMMENCE Mitral Trial: Early Clinical Data Supporting RESILIA Tissue in the Mitral Position

Results at 5 years

Mid-term outcomes of the ongoing COMMENCE mitral IDE trial of 82 patients who underwent MVR in this prospective, single-arm trial.2

79.9%

Freedom from all-cause mortality

98.7%

Freedom from SVD

97.1%

Freedom from reoperation

For more details, download the clinical summary.

COMMENCE Mitral Trial: Results
Explore the clinical data

With a favorable safety profile and clinically stable hemodynamic performance, this study supports the use of RESILIA tissue in the mitral position with excellent durability out to 5 years.

RESILIA tissue valves in the mitral position offer excellent durability out to 5 years

References

  1. Ailawadi G, Heimansohn D, Accola K, et al. One-year safety and performance of a novel bovine pericardial mitral valve with advanced anti-calcification treatment. Presented at the 2026 Society of Thoracic Surgeons Annual Meeting. January 29, 2026.
  2. Heimansohn DA, Baker C, Rodriguez E, et al. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue. JTCVS Open. 2023;15:151-163. Published 2023 Jun 2. doi:10.1016/j.xjon.2023.05.008
  3. Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg. 2008;85(4):1490-1495. doi:10.1016/j.athoracsur.2007.12.082
Medical device for professional use.

Medical device for professional use.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com  where applicable).

PP--EU-1509 v1.0